CN101360820A - 无寡肽的细胞培养基 - Google Patents

无寡肽的细胞培养基 Download PDF

Info

Publication number
CN101360820A
CN101360820A CNA2007800017871A CN200780001787A CN101360820A CN 101360820 A CN101360820 A CN 101360820A CN A2007800017871 A CNA2007800017871 A CN A2007800017871A CN 200780001787 A CN200780001787 A CN 200780001787A CN 101360820 A CN101360820 A CN 101360820A
Authority
CN
China
Prior art keywords
cells
virus
medium
cell culture
oligopeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800017871A
Other languages
English (en)
Chinese (zh)
Inventor
利奥波德·格里伯格
曼弗雷德·赖特
沃尔夫冈·蒙特
阿图尔·米特雷尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter Healthcare SA
Baxter International Inc
Original Assignee
Baxter Healthcare SA
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37942126&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101360820(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Healthcare SA, Baxter International Inc filed Critical Baxter Healthcare SA
Publication of CN101360820A publication Critical patent/CN101360820A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/005—Protein-free medium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/46—Amines, e.g. putrescine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/50—Soluble polymers, e.g. polyethyleneglycol [PEG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CNA2007800017871A 2006-01-04 2007-01-03 无寡肽的细胞培养基 Pending CN101360820A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75641906P 2006-01-04 2006-01-04
US60/756,419 2006-01-04

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2012100603866A Division CN102643777A (zh) 2006-01-04 2007-01-03 无寡肽的细胞培养基

Publications (1)

Publication Number Publication Date
CN101360820A true CN101360820A (zh) 2009-02-04

Family

ID=37942126

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2007800017871A Pending CN101360820A (zh) 2006-01-04 2007-01-03 无寡肽的细胞培养基
CN2012100603866A Pending CN102643777A (zh) 2006-01-04 2007-01-03 无寡肽的细胞培养基

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2012100603866A Pending CN102643777A (zh) 2006-01-04 2007-01-03 无寡肽的细胞培养基

Country Status (17)

Country Link
US (4) US20070212770A1 (enExample)
EP (4) EP3121266B8 (enExample)
JP (6) JP5259418B2 (enExample)
KR (2) KR101423344B1 (enExample)
CN (2) CN101360820A (enExample)
AU (1) AU2007204044B2 (enExample)
CA (1) CA2633306A1 (enExample)
CY (1) CY1119046T1 (enExample)
DK (3) DK1974014T3 (enExample)
ES (3) ES2474573T3 (enExample)
HU (1) HUE032744T2 (enExample)
LT (1) LT1974014T (enExample)
PL (3) PL3121266T3 (enExample)
PT (3) PT3121266T (enExample)
RU (3) RU2486236C2 (enExample)
SI (1) SI2522717T1 (enExample)
WO (1) WO2007077217A2 (enExample)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104962539A (zh) * 2009-07-31 2015-10-07 巴克斯特国际公司 用于adamts蛋白表达的细胞培养基
CN105143444A (zh) * 2013-03-15 2015-12-09 瑞泽恩制药公司 无血清细胞培养基
CN106635953A (zh) * 2016-12-13 2017-05-10 昆明润什生物科技有限公司 无血清无蛋白细胞培养基
CN107406368A (zh) * 2015-03-17 2017-11-28 帝斯曼知识产权资产管理有限公司 用于制备二氨基丁烷的工艺
GB2578370A (en) * 2018-05-10 2020-05-06 Univ Jiangsu Device for detecting service life of electronic component
US10927342B2 (en) 2015-08-04 2021-02-23 Regeneran Pharmaceuticals, Inc. Taurine supplemented cell culture medium and methods of use
CN113151183A (zh) * 2021-04-21 2021-07-23 赵峻岭 一种促进蛋白表达的培养基添加物及其应用
CN114667351A (zh) * 2019-11-05 2022-06-24 味之素株式会社 蛋白质的制造方法
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101423344B1 (ko) 2006-01-04 2014-07-30 백스터 인터내셔널 인코포레이티드 올리고펩티드-무함유 세포 배양 배지를 이용하여 단백질을 발현시키는 방법
SI2235197T1 (sl) 2007-12-27 2017-10-30 Baxalta GmbH Procesi celične kulture
MX2010007344A (es) * 2007-12-31 2010-11-09 Baxter Int Furina recombinante substancialmente libre de proteina animal y metodos para la produccion de la misma.
DK2250251T3 (en) 2008-01-09 2018-01-22 Sartorius Stedim Cellca Gmbh Improved culture medium additive and method of using it
EP2257622B1 (en) * 2008-02-25 2017-03-22 Nanotherapeutics, Inc. Method for producing continuous cell lines
HRP20151054T4 (hr) * 2008-11-12 2019-11-15 Baxalta Inc Postupak proizvodnje faktora vii bez seruma, bez inzulina
US8580554B2 (en) 2009-07-31 2013-11-12 Baxter International Inc. Method of producing a polypeptide or virus of interest in a continuous cell culture
PL4218797T3 (pl) 2009-09-21 2025-02-10 Takeda Pharmaceutical Company Limited Stabilizowane płynne i liofilizowane preparaty adamts13
US8986957B2 (en) 2010-04-26 2015-03-24 Novartis Ag Cell culture medium
CN103097522A (zh) * 2010-07-08 2013-05-08 巴克斯特国际公司 在细胞培养物中生产重组adamts13的方法
TWI621625B (zh) 2010-09-17 2018-04-21 巴克斯歐塔公司 在弱酸性至中性ｐｈ中經由具有組胺酸的水性調配物穩定免疫球蛋白
TWI580430B (zh) 2010-10-27 2017-05-01 巴克斯歐塔公司 用於免疫耐受誘導及免疫診斷之ｆｖｉｉｉ胜肽
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
EP3858375B1 (en) 2011-06-10 2024-03-20 Takeda Pharmaceutical Company Limited Treatment of coagulation disease by administration of recombinant vwf
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
EP2906683B1 (en) 2012-10-15 2017-05-31 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
HK1207960A1 (en) 2013-03-12 2016-02-19 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
KR101641655B1 (ko) * 2014-01-08 2016-07-21 서울대학교산학협력단 스퍼미딘 또는 스퍼민을 이용함으로써 생육 저해제에 대한 내성이 증진된 효모의 배양방법
JP6624985B2 (ja) * 2015-03-27 2019-12-25 日清ファルマ株式会社 ポリアミン高含有酵母
US12209261B2 (en) 2015-12-02 2025-01-28 CSL Behring Lengnau AG Media for the expression of recombinant vitamin K-dependent proteins
EP3967765A1 (en) * 2017-07-06 2022-03-16 FrieslandCampina Nederland B.V. Cell culture process for making a glycoprotein
FI3648787T3 (fi) 2017-07-07 2025-01-20 Takeda Pharmaceuticals Co Elektiiviseen leikkaustoimenpiteeseen osallistuvien vaikeaa von willebrandin tautia sairastavien potilaiden hoito antamalla rekombinanttia vwf:ää
AU2018298233B2 (en) 2017-07-07 2025-04-24 Takeda Pharmaceutical Company Limited Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant VWF
JP2021519280A (ja) 2018-03-21 2021-08-10 バクスアルタ インコーポレイテッド クロマトグラフィー法によるｖｗｆとｖｗｆプロペプチドの分離
LT3781943T (lt) 2018-04-20 2022-07-11 Janssen Biotech, Inc. Chromatografinės kolonos kvalifikavimas gamybinių metodų, skirtų pagaminti anti-il-12/il-23 antikūnų kompozicijas, metu
EP3880824B1 (en) 2018-11-13 2024-07-24 Janssen Biotech, Inc. Control of trace metals during production of anti-cd38 antibodies
WO2020150411A1 (en) 2019-01-17 2020-07-23 Boehringer Ingelheim Animal Health USA Inc. Serum-free medium for avian vaccine production and uses thereof
CA3128498A1 (en) 2019-02-01 2020-08-06 Bjorn Mellgard Methods of prophylactic treatment using recombinant vwf (rvwf)
CA3133381A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
WO2020183271A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Methods for producing anti-tnf antibody compositions
CN113825769A (zh) 2019-03-14 2021-12-21 詹森生物科技公司 用于产生抗tnf抗体组合物的方法
CN113825765A (zh) 2019-03-14 2021-12-21 詹森生物科技公司 用于制备抗il12/il23抗体组合物的制造方法
WO2020201296A1 (en) 2019-04-01 2020-10-08 The Automation Partnership (Cambridge) Ltd. Operation process for a cell cultivation system
EP4028046B1 (en) 2019-09-11 2024-02-14 Takeda Pharmaceutical Company Limited Methods of treatment related to complexes of von willebrand factor and complement c1q
KR20230152810A (ko) 2019-12-06 2023-11-03 리제너론 파아마슈티컬스, 인크. 항-vegf 단백질 조성물 및 이를 생산하는 방법
WO2021158777A1 (en) 2020-02-04 2021-08-12 Baxalta Incorporated Treatment of menorrhagia in patients with severe von willebrand disease by administration of recombinant vwf
US20230203469A1 (en) 2020-04-02 2023-06-29 Takeda Pharmaceutical Company Limited Adamts13 variant, compositions, and uses thereof
JP2023525034A (ja) 2020-05-08 2023-06-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｖｅｇｆトラップおよびミニトラップならびに眼障害およびがんの治療方法
US12031151B2 (en) 2021-01-20 2024-07-09 Regeneron Pharmaceuticals, Inc. Methods of improving protein titer in cell culture
US20230042465A1 (en) 2021-07-09 2023-02-09 Janssen Biotech, Inc. Manufacturing Methods for Producing Anti-TNF Antibody Compositions
CN117916260A (zh) 2021-07-09 2024-04-19 詹森生物科技公司 用于制备抗il12/il23抗体组合物的制造方法
KR20240167717A (ko) 2022-03-02 2024-11-27 리제너론 파아마슈티컬스, 인크. 항체 생산을 위한 세포 배양 방법
CA3266599A1 (en) 2022-09-07 2024-11-07 Quantitative Biosciences, Inc. UNIQUE VARIABLE DOMAIN ANTIBODIES SPECIFIC TO FENTANYL AND USE IN A CONTINUOUS AGGLUTINATION TEST
WO2025053166A1 (ja) * 2023-09-05 2025-03-13 味の素株式会社 培地組成物
WO2025128343A1 (en) 2023-12-11 2025-06-19 Just-Evotec Biologics, Inc. Protein expression using trans-splicing and split selectable markers
WO2025210223A1 (en) * 2024-04-04 2025-10-09 Sartorius Xell GmbH Methods for viral vector production with reduced host cell aggregation and methods for dissolving host cell aggregates

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT165999B (de) 1947-06-26 1950-05-25 Delle Atel Const Electr Einirchtung zum Schutz von Drehstrommotoren gegen Überstrom
US4443540A (en) * 1980-05-09 1984-04-17 University Of Illinois Foundation Protein hydrolysis
DK207980A (da) * 1980-05-13 1981-11-14 Novo Industri As Fremgangsmaade til fremstilling af et skumnings- eller emulgeringsmiddel paa sojaproteinbasis
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
FR2543158B1 (fr) 1983-03-24 1985-11-15 Inst Nat Sante Rech Med Milieu de culture de cellules animales sans serum, sans hormones et sans facteurs de croissance et procedes de culture primaire et d'obtention de lignees cellulaires utilisant ce milieu
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
FI86885C (fi) 1984-04-20 1992-10-26 Genentech Inc Foerfarande foer framstaellning av human rekombinantfaktor viii och nukleinsyrasekvenser och vektorer anvaend daertill
DE3688418T2 (de) 1985-02-13 1993-08-26 Scios Nova Inc Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen.
US4978616A (en) * 1985-02-28 1990-12-18 Verax Corporation Fluidized cell cultivation process
DE3787805T2 (de) 1986-08-04 1994-02-10 Garvan Inst Med Res Serumfreies gewebekulturmedium, das ein polymerzellenschutzmittel enthält.
US5045468A (en) 1986-12-12 1991-09-03 Cell Enterprises, Inc. Protein-free culture medium which promotes hybridoma growth
JPH01503679A (ja) 1987-06-30 1989-12-14 アムジエン・インコーポレーテツド カリクレインの生産
JP2507882B2 (ja) 1988-02-17 1996-06-19 工業技術院長 外部増殖因子非依存性増殖良好細胞株の製造法
US6048728A (en) * 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
US5573937A (en) * 1989-12-07 1996-11-12 Snow Brand Milk Products Co., Ltd. Serum free culture medium
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
JPH0789954B2 (ja) 1990-01-22 1995-10-04 アメリカ合衆国 細胞の保存と増殖のための二酸化炭素―非依存性増殖培地
JP2844484B2 (ja) 1990-02-22 1999-01-06 味の素株式会社 組換え蛋白質の生産方法
JP2859679B2 (ja) 1990-03-01 1999-02-17 協和醗酵工業株式会社 新規細胞株
US5378612A (en) * 1990-05-11 1995-01-03 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Culture medium for production of recombinant protein
JP2696001B2 (ja) 1991-04-15 1998-01-14 財団法人化学及血清療法研究所 組換え蛋白質産生用培地
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
AU643077B2 (en) 1990-10-19 1993-11-04 Unilever Plc Detergent compositions
JPH04228066A (ja) 1990-10-23 1992-08-18 Rikagaku Kenkyusho 外来遺伝子発現用培養細胞
EP0531562A1 (de) * 1991-09-11 1993-03-17 Doerr, Hans-Wilhelm, Prof. Dr. med. Kultivierung von Säugetierzellen
CA2078721A1 (en) 1991-09-24 1993-03-25 Hiroshi Yonemura Process for preparing human coagulation factor viii protein complex
JPH05123178A (ja) 1991-11-01 1993-05-21 Ajinomoto Co Inc Ｌ−フエニルアラニンの製造法
AU7895898A (en) 1993-04-26 1998-10-08 Hans Wolf Mammal cell lines and method of obtaining glycoproteins
DE4313620A1 (de) 1993-04-26 1994-10-27 Biotechnolog Forschung Gmbh Hamsterzellinien und Verfahren zur Glykoproteingewinnung
GB9311132D0 (en) * 1993-05-28 1993-07-14 Eisai London Res Lab Ltd Control of cell death
US5405637A (en) 1993-06-30 1995-04-11 Bristol-Myers Squibb Company Milk protein partial hydrolysate and infant formula containing same
JP2766165B2 (ja) 1993-08-02 1998-06-18 株式会社バイオポリマー・リサーチ バクテリアセルロースの製造方法
US5445956A (en) * 1993-08-13 1995-08-29 The Regents Of The University Of California Recombinant soluble epoxide hydrolase
EP0653487A1 (de) 1993-11-07 1995-05-17 Ferruccio Dr. Messi Serum- und proteinfrei wachsende Zellen
US5719050A (en) * 1993-12-24 1998-02-17 Eiken Chemical Co., Ltd. Animal cell culturing media containing N-acetyl-L-glutamic acid
US5498599A (en) * 1994-01-21 1996-03-12 Amgen Inc. Methods for stimulating platelet production
EP0666312A1 (en) 1994-02-08 1995-08-09 Wolfgang A. Renner Process for the improvement of mammalian cell growth
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5789247A (en) * 1994-04-01 1998-08-04 Ballay; Annick Expression in non-tumoral human lymphoblastoid lines with an integrative vector
WO1996007730A2 (de) 1994-09-09 1996-03-14 Renner Wolfgang A Chemisches verfahren zur förderung der proliferation von tierischen zellen
ES2323490T3 (es) 1994-11-10 2009-07-17 Baxter Healthcare Sa Procedimiento de produccion de agentes biologicos en un medio de cultivo sin proteinas.
AT403167B (de) 1994-11-14 1997-11-25 Immuno Ag Selektion und expression von fremdproteinen mittels eines selektions-amplifikations-systems
EP0799310A1 (en) 1994-12-16 1997-10-08 Novartis AG Production of recombinant secretory component
DE69608668T2 (de) 1995-02-23 2001-02-01 Quest International B.V., Naarden Peptide für gewebe- und zellkulturmedien
US5741705A (en) * 1995-02-23 1998-04-21 Quest International Flavors & Food Ingredients Company, Division Of Indopco, Inc. Method for in vitro cell growth of eucaryotic cells using low molecular weight peptides
AU6125396A (en) 1995-06-07 1996-12-30 Novartis Ag Serum-free media for primitive hematopoietic cells and metho ds of use thereof
AUPN442295A0 (en) 1995-07-26 1995-08-17 Commonwealth Scientific And Industrial Research Organisation Regulated autocrine growth of mammalian cells
US5851800A (en) * 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
EP0953041A4 (en) 1996-08-30 2003-01-29 Life Technologies Inc SERUM-FREE CULTURAL MEDIUM FOR MAMMAL CELLS AND THEIR USE
WO1998008935A1 (en) 1996-08-30 1998-03-05 The University Of North Carolina At Chapel Hill Immortalized human hepatic cell line
US6103529A (en) 1996-10-10 2000-08-15 Life Technologies, Inc. Animal cell culture media comprising peptides derived from rice
US5804420A (en) * 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
WO1998054296A1 (en) 1997-05-28 1998-12-03 Chiron S.P.A. Culture medium with yeast or soy bean extract as aminoacid source and no protein complexes of animal origin
AT407255B (de) * 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
US6475725B1 (en) * 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
JP4541539B2 (ja) 1997-07-23 2010-09-08 ロシュ ダイアグノスティックス ゲーエムベーハー 内因性遺伝子活性化によるエリスロポエチンの製造
CA2309258C (en) 1997-11-20 2012-05-01 Weyerhaeuser Company Nutritive media and manufactured seeds comprising same
WO1999035255A2 (en) * 1998-01-12 1999-07-15 Betagene, Inc. Compositions and methods for regulated secretion from neuroendocrine cell lines
FR2775983B1 (fr) 1998-03-13 2000-11-10 Pasteur Merieux Serums Vacc Milieu et procede de propagation et de multiplication virales
WO1999057246A1 (en) 1998-05-01 1999-11-11 Life Technologies, Inc. Animal cell culture media comprising non-animal or plant-derived nutrients
US6537782B1 (en) * 1998-06-01 2003-03-25 Chugai Seiyaku Kabushiki Kaisha Media for culturing animal cells and process for producing protein by using the same
US6406909B1 (en) 1998-07-10 2002-06-18 Chugai Seiyaku Kabushiki Kaisha Serum-free medium for culturing animal cells
JP4266055B2 (ja) 1999-03-04 2009-05-20 雪印乳業株式会社 ポリアミン組成物の製造法
AT409379B (de) * 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
EP1200561B1 (de) 1999-08-05 2006-06-14 Baxter Aktiengesellschaft Rekombinanter stabiler zellklon, seine herstellung und verwendung
NZ517215A (en) 1999-08-25 2004-01-30 Immunex Corp Compositions and methods for improved cell culture
US6596526B1 (en) * 2000-06-09 2003-07-22 Baxter Aktiengesellschaft Furin polypeptides with improved characteristics
EP1358319B1 (en) 2000-09-25 2009-06-17 Polymun Scientific Immunbiologische Forschung GmbH Live influenza vaccine and method of manufacture
EP1208966A1 (en) 2000-11-27 2002-05-29 Cheng-Kun Liao Manufacturing process of patio tabletop glass with broken protection
DE10059175A1 (de) 2000-11-29 2002-06-20 Siemens Ag Verfahren und Vorrichtung zur Anrufumleitung mittels eines Stellvertreters in einem Kommunikationssystem
US20030096414A1 (en) 2001-03-27 2003-05-22 Invitrogen Corporation Culture medium for cell growth and transfection
US6734289B2 (en) * 2001-03-29 2004-05-11 The University Of Chicago Gastrokines and derived peptides including inhibitors
AU2002316230A1 (en) 2001-06-13 2002-12-23 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells
US7037658B2 (en) * 2001-08-16 2006-05-02 Regents Of University Of Michigan Methods and compositions for detecting variant ADAMTS13 genes
WO2003029442A1 (en) 2001-10-02 2003-04-10 Novo Nordisk Health Care Ag Method for production of recombinant proteins in eukaryote cells
US20030104527A1 (en) * 2001-12-03 2003-06-05 National Research Council Of Canada Methylotrophic bacterium for the production of recombinant proteins and other products
DE10161412A1 (de) * 2001-12-13 2003-07-03 Aventis Pharma Gmbh Verfahren zur Bestimmung der Aktivität der Ornithin-Decarboxylase sowie zur Identifizierung von Effektoren der Ornithin-Decarboxylase-Aktivität
JP2005532057A (ja) 2002-07-09 2005-10-27 バクスター・インターナショナル・インコーポレイテッド 細胞を培養するための動物性タンパク質非含有培地
FR2846004B1 (fr) 2002-10-16 2006-06-23 Maco Pharma Sa Composition pour culture de cellules notamment animales ou de tissus, comprenant du polyethylene glycol
FR2846005B1 (fr) 2002-10-16 2006-06-23 Maco Pharma Sa Composition pour milieu biologique comprenant de l'erythorbate de sodium
DE10333675A1 (de) 2003-07-24 2005-03-03 Aventis Pharma Deutschland Gmbh Perfusionsverfahren für die Produktion von Erythropoietin
WO2005035748A1 (en) 2003-10-10 2005-04-21 Novo Nordisk Health Care Ag Method for large-scale production of a polypeptide in eukaryote cells and a culture vessel suitable therefor
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
US20060094104A1 (en) * 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
AU2005302516A1 (en) 2004-10-29 2006-05-11 Centocor, Inc. Chemically defined media compositions
KR101423344B1 (ko) 2006-01-04 2014-07-30 백스터 인터내셔널 인코포레이티드 올리고펩티드-무함유 세포 배양 배지를 이용하여 단백질을 발현시키는 방법

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104962539B (zh) * 2009-07-31 2019-09-17 百深公司 用于adamts蛋白表达的细胞培养基
CN104962539A (zh) * 2009-07-31 2015-10-07 巴克斯特国际公司 用于adamts蛋白表达的细胞培养基
US11970724B2 (en) 2013-03-15 2024-04-30 Regeneron Pharmaceuticals, Inc. Serum-free cell culture medium
US12331341B2 (en) 2013-03-15 2025-06-17 Regeneron Pharmaceuticals, Inc. Serum-free cell culture medium
CN105143444A (zh) * 2013-03-15 2015-12-09 瑞泽恩制药公司 无血清细胞培养基
US11332771B2 (en) 2013-03-15 2022-05-17 Regeneron Pharmaceuticals, Inc. Serum-free cell culture medium
CN107406368A (zh) * 2015-03-17 2017-11-28 帝斯曼知识产权资产管理有限公司 用于制备二氨基丁烷的工艺
US11312936B2 (en) 2015-08-04 2022-04-26 Regeneron Pharmaceuticals, Inc. Taurine supplemented cell culture medium and methods of use
US10927342B2 (en) 2015-08-04 2021-02-23 Regeneran Pharmaceuticals, Inc. Taurine supplemented cell culture medium and methods of use
US12221619B2 (en) 2015-08-04 2025-02-11 Regeneron Pharmaceuticals Inc. Taurine supplemented cell culture medium and methods of use
US12359166B2 (en) 2015-08-04 2025-07-15 Regeneron Pharmaceuticals, Inc. Taurine supplemented cell culture medium and methods of use
US12359165B2 (en) 2015-08-04 2025-07-15 Regeneron Pharmaceuticals, Inc. Taurine supplemented cell culture medium and methods of use
CN106635953B (zh) * 2016-12-13 2021-02-19 昆明润什生物科技有限公司 无血清无蛋白细胞培养基
CN106635953A (zh) * 2016-12-13 2017-05-10 昆明润什生物科技有限公司 无血清无蛋白细胞培养基
GB2578370A (en) * 2018-05-10 2020-05-06 Univ Jiangsu Device for detecting service life of electronic component
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
CN114667351A (zh) * 2019-11-05 2022-06-24 味之素株式会社 蛋白质的制造方法
CN113151183A (zh) * 2021-04-21 2021-07-23 赵峻岭 一种促进蛋白表达的培养基添加物及其应用

Also Published As

Publication number Publication date
DK3121266T3 (da) 2020-05-11
RU2642269C2 (ru) 2018-01-24
EP3121266B8 (en) 2020-04-22
KR20130100224A (ko) 2013-09-09
US20160068587A1 (en) 2016-03-10
CY1119046T1 (el) 2018-01-10
EP2522717B1 (en) 2014-04-02
KR101422435B1 (ko) 2014-07-22
RU2013112019A (ru) 2014-09-27
AU2007204044A1 (en) 2007-07-12
RU2017144220A3 (enExample) 2021-03-01
RU2017144220A (ru) 2019-06-18
DK2522717T3 (da) 2014-04-22
HK1177950A1 (en) 2013-08-30
RU2642269C9 (ru) 2018-10-31
ES2629304T3 (es) 2017-08-08
CN102643777A (zh) 2012-08-22
RU2486236C2 (ru) 2013-06-27
ES2474573T3 (es) 2014-07-09
US10696731B2 (en) 2020-06-30
JP2015006209A (ja) 2015-01-15
US9758568B2 (en) 2017-09-12
LT1974014T (lt) 2017-11-27
HUE032744T2 (en) 2017-10-30
JP7134157B2 (ja) 2022-09-09
JP5259418B2 (ja) 2013-08-07
PL2522717T3 (pl) 2014-08-29
WO2007077217A3 (en) 2007-11-08
ES2790887T3 (es) 2020-10-29
RU2758802C2 (ru) 2021-11-02
PT2522717E (pt) 2014-05-15
PT1974014T (pt) 2017-05-26
WO2007077217A2 (en) 2007-07-12
AU2007204044B2 (en) 2012-09-27
JP2013106616A (ja) 2013-06-06
US20070212770A1 (en) 2007-09-13
EP1974014A2 (en) 2008-10-01
JP2009521941A (ja) 2009-06-11
EP2522717A1 (en) 2012-11-14
US20110151512A1 (en) 2011-06-23
EP1974014B1 (en) 2017-04-19
SI2522717T1 (sl) 2014-05-30
CA2633306A1 (en) 2007-07-12
DK1974014T3 (en) 2017-06-19
RU2008131953A (ru) 2010-02-10
PL1974014T3 (pl) 2017-09-29
KR20080083197A (ko) 2008-09-16
JP6567490B2 (ja) 2019-08-28
KR101423344B1 (ko) 2014-07-30
US20170362300A1 (en) 2017-12-21
EP3653699A1 (en) 2020-05-20
JP2017055770A (ja) 2017-03-23
PL3121266T3 (pl) 2020-07-13
EP3121266A1 (en) 2017-01-25
EP3121266B1 (en) 2020-02-26
JP2020028307A (ja) 2020-02-27
PT3121266T (pt) 2020-05-19
JP2018075032A (ja) 2018-05-17

Similar Documents

Publication Publication Date Title
JP7134157B2 (ja) 無オリゴペプチド細胞培地
CN101065480B (zh) 用于细胞培养的无动物蛋白培养基
HK40026826A (en) Oligopeptide-free cell culture media
HK1174951A (en) Oligopeptide-free cell culture media
HK1177950B (en) Oligopeptide-free cell culture media
HK1147110B (en) Animal protein-free media for cultivation of cells
HK1147284B (en) Animal protein-free media for cultivation of cells

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20090204